Shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) reached a new 52-week low on Tuesday . The stock traded as low as $9.73 and last traded at $10.40, with a volume of 82,710 shares traded. The stock had previously closed at $11.29.

Several analysts have weighed in on the stock. HC Wainwright assumed coverage on shares of Syros Pharmaceuticals in a research note on Monday, July 18th. They issued a “neutral” rating and a $10.00 price target for the company. Cowen and Company assumed coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “outperform” rating on the stock. JMP Securities assumed coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “outperform” rating and a $22.00 price objective on the stock. Wedbush assumed coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “outperform” rating and a $18.00 price objective on the stock. Finally, Piper Jaffray Cos. assumed coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “overweight” rating and a $20.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $17.50.

The stock’s 50-day moving average price is $0.00 and its 200-day moving average price is $0.00. The stock’s market cap is $100.56 million.

In related news, major shareholder Redmile Group, Llc bought 432,746 shares of the business’s stock in a transaction that occurred on Wednesday, July 6th. The stock was bought at an average cost of $12.50 per share, with a total value of $5,409,325.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert Nelsen bought 400,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 6th. The shares were bought at an average cost of $12.50 per share, with a total value of $5,000,000.00. The disclosure for this purchase can be found here.

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.